This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
5 Small-Cap ETFs & Stocks Beating Russell 2000
by Sweta Killa
We have presented five ETFs & stocks that have easily crushed the Russell 2000 index this year and are likely to continue their strong performance.
Why Materials & Mining ETFs Are Riding Higher
by Sanghamitra Saha
Plenty of factors have been pushing materials, and metal and mining ETFs higher of late.
Market on Track for Worst December: 5 ETFs Losers
by Sweta Killa
U.S. stocks are on track for the worst December since the Great Depression in 1931. We have highlighted five funds that have been hit badly in the market turmoil.
Gear Up for Q3 Earnings With These Small-Cap Sector ETFs
by Sanghamitra Saha
These sector ETFs under the small-cap index S&P 600 appear well positioned this earnings season.
Top and Flop ETFs of Last Week
by Sweta Killa
We have highlighted the best and worst performing ETFs of the last week.
Play 4 Sector ETFs With Strong Beat Ratios
by Sanghamitra Saha
Inside the sector ETFs that have come up with great beat ratios this reporting cycle.
Solid Small-Cap Earnings Put Spotlight on These Sector ETFs
by Sanghamitra Saha
Small-cap stocks recorded stellar earnings in Q1, bringing these sector ETFs into focus.
Putting Up the Tree with the Promising ETFs of 2017
by Sweta Killa
We have built a tree with the most verdant ETFs of 2016 that could stand tall in 2017.
The Zacks Analyst Blog Highlights: iShares Russell 2000, PowerShares S&P Small-Cap Materials ETF, First Trust NASDAQ ABA Community Bank ETF, Guggenheim S&P SmallCap 600 Pure Value ETF and First Trust RBA American Industrial Renaissance ETF
by Zacks Equity Research
The Zacks Analyst Blog Highlights: iShares Russell 2000, PowerShares S&P Small-Cap Materials ETF, First Trust NASDAQ ABA Community Bank ETF, Guggenheim S&P SmallCap 600 Pure Value ETF and First Trust RBA American Industrial Renaissance ETF
The Zacks Analyst Blog Highlights: BioShares Biotechnology Clinical Trials Fund, Guggenheim S&P SmallCap 600 Pure Value ETF, PowerShares S&P SmallCap Materials Fund, Health Insurance Innovations and Airgain
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BioShares Biotechnology Clinical Trials Fund, Guggenheim S&P SmallCap 600 Pure Value ETF, PowerShares S&P SmallCap Materials Fund, Health Insurance Innovations and Airgain